Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET) Abstract #57

Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.
Aim(s): This retrospective observational claims-based study describes patients' clinical and demographic characteristics at the time of initial diagnosis, as well as major cardiovascular events in the first three years post-diagnosis.
Materials and methods: Study patients consisted of adults newly diagnosed with one of the following specific NET ICD9-CM codes: 157.4 (islet cell, n=149), 209.xx (carcinoid, n=0), 258.01 (MEN1, n=0), or 259.2 (carcinoid syndrome, n=1181) from October 2001 to September 2006. Patients were required to have at least three years follow-up in SDI Health’s medical claims. Patients' clinical and demographic characteristics were measured at baseline, and cardiovascular events were captured in the follow-up period.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Chi-Chang Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2727 Gastroenteropancreatic Neuroendocrine Tumours versus Gastroenteropancreatic Neuroendocrine Carcinoma: Presentation in Tunisian Patients
Introduction: Neuroendocrine neoplasms (NENs) are divided into two groups on the basis of clinical behaviour, histology, and proliferation rate: well differentiated (low grade to intermediate grade) neuroendocrine tumors and poorly differentiated (high grade) neuroendocrine carcinoma.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira
#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David C. Metz
Authors: Metz D C, Liu E, Joish V N, Huynh L, ...